Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology : a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. / Matz, Jørgen; Graff, Claus; Vainio, Petri J.; Kallio, Antero; Højer, Astrid Maria; Struijk, Johannes J.; Kanters, Jørgen K.; Andersen, Mads Peter; Toft, Egon.

I: Clinical Drug Investigation, Bind 31, Nr. 11, 2011, s. 799-811.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Matz, J, Graff, C, Vainio, PJ, Kallio, A, Højer, AM, Struijk, JJ, Kanters, JK, Andersen, MP & Toft, E 2011, 'Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study', Clinical Drug Investigation, bind 31, nr. 11, s. 799-811. https://doi.org/10.1007/BF03256919

APA

Matz, J., Graff, C., Vainio, P. J., Kallio, A., Højer, A. M., Struijk, J. J., Kanters, J. K., Andersen, M. P., & Toft, E. (2011). Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clinical Drug Investigation, 31(11), 799-811. https://doi.org/10.1007/BF03256919

Vancouver

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ o.a. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clinical Drug Investigation. 2011;31(11):799-811. https://doi.org/10.1007/BF03256919

Author

Matz, Jørgen ; Graff, Claus ; Vainio, Petri J. ; Kallio, Antero ; Højer, Astrid Maria ; Struijk, Johannes J. ; Kanters, Jørgen K. ; Andersen, Mads Peter ; Toft, Egon. / Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology : a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. I: Clinical Drug Investigation. 2011 ; Bind 31, Nr. 11. s. 799-811.

Bibtex

@article{9eac4736acbe412eadb2ecb6462ed5ce,
title = "Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study",
abstract = "Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).",
keywords = "Adult, Anti-Infective Agents, Arrhythmias, Cardiac, Aza Compounds, Biomarkers, Pharmacological, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Guidelines as Topic, Heart Rate, Humans, Long QT Syndrome, Male, Naltrexone, Narcotic Antagonists, Placebos, Prospective Studies, Quinolines, Treatment Outcome, Young Adult",
author = "J{\o}rgen Matz and Claus Graff and Vainio, {Petri J.} and Antero Kallio and H{\o}jer, {Astrid Maria} and Struijk, {Johannes J.} and Kanters, {J{\o}rgen K.} and Andersen, {Mads Peter} and Egon Toft",
year = "2011",
doi = "10.1007/BF03256919",
language = "English",
volume = "31",
pages = "799--811",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology

T2 - a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study

AU - Matz, Jørgen

AU - Graff, Claus

AU - Vainio, Petri J.

AU - Kallio, Antero

AU - Højer, Astrid Maria

AU - Struijk, Johannes J.

AU - Kanters, Jørgen K.

AU - Andersen, Mads Peter

AU - Toft, Egon

PY - 2011

Y1 - 2011

N2 - Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).

AB - Nalmefene is an orally administered competitive opioid receptor antagonist targeted at reducing alcohol consumption in alcohol-dependent patients. As part of the regulatory requirements for drug approval, the potential of novel compounds for causing unwanted proarrhythmia should be studied in a thoroughly designed clinical QT/corrected QT (QTc) study (International Conference on Harmonisation [ICH] E14 guideline).

KW - Adult

KW - Anti-Infective Agents

KW - Arrhythmias, Cardiac

KW - Aza Compounds

KW - Biomarkers, Pharmacological

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Electrocardiography

KW - Female

KW - Guidelines as Topic

KW - Heart Rate

KW - Humans

KW - Long QT Syndrome

KW - Male

KW - Naltrexone

KW - Narcotic Antagonists

KW - Placebos

KW - Prospective Studies

KW - Quinolines

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1007/BF03256919

DO - 10.1007/BF03256919

M3 - Journal article

C2 - 21967071

VL - 31

SP - 799

EP - 811

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 11

ER -

ID: 48052162